Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-cycloserine augmentation of intermittent theta burst stimulation for major depressive disorder
ACTRN12622001359729Phase 2Terminated
- Sponsor
- Alfred Health
- Start
- Apr 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of d-cycloserine in major depressive disorder (MDD) and major depressive episode (MDE) (3 arms), sponsored by Alfred Health. Primary endpoint: Montgomery-Åsberg Depression Rating Scale. Started Apr 2023; status: terminated.
02
Drugs
d-cycloserine
03
Conditions
major depressive disorder (MDD)major depressive episode (MDE)
Beyond the preview
Go deeper on ACTRN12622001359729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001359729.